[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension]

Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6.
[Article in German]

Abstract

Riociguat is the first clinically available soluble Guanylate-cyclase stimulator (sGC) and representative of a completely new class of drugs. Riociguat is approved for pulmonary arterial hypertension (PAH) and non-operable or recurrent/persistent chronic thromboembolic pulmonary hypertension (CTEPH). Moreover, Riociguat is currently under investigation for a wider spectrum of diseases. This article focusses on its mode of action and clinical trial data. Finally, based on these data, the status of approval, as well as the costs a proposal is given how Riociguat can be integrated in the current treatment of PAH and CTEPH.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / administration & dosage
  • Chronic Disease
  • Fibrinolytic Agents / administration & dosage
  • Guanylate Cyclase / metabolism*
  • Humans
  • Hypertension, Pulmonary / complications
  • Hypertension, Pulmonary / drug therapy*
  • Hypertension, Pulmonary / metabolism*
  • Pulmonary Embolism / complications
  • Pulmonary Embolism / drug therapy*
  • Pulmonary Embolism / metabolism*
  • Pyrazoles / administration & dosage*
  • Pyrazoles / pharmacokinetics
  • Pyrimidines / administration & dosage*
  • Pyrimidines / pharmacokinetics
  • Receptors, Cytoplasmic and Nuclear / agonists
  • Receptors, Cytoplasmic and Nuclear / metabolism*
  • Soluble Guanylyl Cyclase
  • Treatment Outcome

Substances

  • Antihypertensive Agents
  • Fibrinolytic Agents
  • Pyrazoles
  • Pyrimidines
  • Receptors, Cytoplasmic and Nuclear
  • Guanylate Cyclase
  • Soluble Guanylyl Cyclase
  • riociguat